Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

Effect of LY2062430 on the Progression of Alzheimer's Disease

Phase 3

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Placebo
Drug: LY2062430

First Posted Date: 2009-05-20

Last Posted Date: 2012-12-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 1040

Registration Number: NCT00904683

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Swindon, Wiltshire, United Kingdom

A Study of Thymidylate Synthase Expression in Patients With Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: pemetrexed
Drug: cisplatin

First Posted Date: 2009-04-24

Last Posted Date: 2012-06-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 70

Registration Number: NCT00887549

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom

A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture

Phase 4

Completed

Conditions: Osteoporosis

Interventions: Drug: Teriparatide
Drug: Risedronate
Drug: Placebo
Dietary Supplement: Calcium
Dietary Supplement: Vitamin D

First Posted Date: 2009-04-24

Last Posted Date: 2019-09-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 224

Registration Number: NCT00887354

Locations: 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain

Study of IMC-EB10 in Participant With Leukemia

Phase 1

Terminated

Conditions: Myeloid Leukemia

Interventions: Biological: IMC-EB10

First Posted Date: 2009-04-24

Last Posted Date: 2022-12-22

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 25

Registration Number: NCT00887926

Locations: 🇺🇸
ImClone Investigational Site, Houston, Texas, United States

A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

Phase 2

Completed

Conditions: Relapsing-Remitting Multiple Sclerosis

Interventions: Drug: LY2127399
Drug: Placebo

First Posted Date: 2009-04-17

Last Posted Date: 2018-11-15

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 245

Registration Number: NCT00882999

Locations: 🇺🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zaporizhzhya, Ukraine

Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment

Phase 2

Completed

Conditions: Migraine Disorders

Interventions: Drug: Placebo
Drug: Lasmiditan

First Posted Date: 2009-04-17

Last Posted Date: 2019-12-23

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 512

Registration Number: NCT00883051

A Study for Participants With Type 2 Diabetes Mellitus

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: LY2409021

First Posted Date: 2009-03-30

Last Posted Date: 2018-04-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 87

Registration Number: NCT00871572

Locations: 🇱🇹
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vilnius, Lithuania

A Study for Patients With Multiple Sclerosis

Phase 2

Terminated

Conditions: Secondary Progressive Multiple Sclerosis

Interventions: Drug: dirucotide

First Posted Date: 2009-03-27

Last Posted Date: 2010-09-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 546

Registration Number: NCT00870155

Locations: 🇩🇰
Copenhagen University Hospital, Kobenhavn, Denmark
🇪🇪
West Tallinn Central Hospital, Tallinn, Estonia
🇨🇦
St. Michaels Hospital, Toronto, Ontario, Canada

and more 7 locations

A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Gemcitabine
Drug: Cisplatin
Biological: Cetuximab
Biological: IMC-A12 (cixutumumab)
Drug: Carboplatin

First Posted Date: 2009-03-27

Last Posted Date: 2018-06-01

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 64

Registration Number: NCT00870870

Locations: 🇺🇸
ImClone Investigational Site, Cincinnati, Ohio, United States

A Study for Patients With Secondary Progressive Multiple Sclerosis

Phase 2

Completed

Conditions: Secondary Progressive Multiple Sclerosis

Interventions: Drug: Placebo
Drug: dirucotide

First Posted Date: 2009-03-26

Last Posted Date: 2010-06-02

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 596

Registration Number: NCT00869726

Locations: 🇱🇻
Vecmilgravis Hospital, Riga, Latvia
🇪🇪
West Tallinn Central Hospital, Tallinn, Estonia
🇫🇮
Terveystalo Turku Kuvantaminen, Turku, Finland

and more 7 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy